Abstract
Background: Preliminary data from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients indicate that a cytokine storm may increase morbidity and mortality. Tocilizumab (anti-IL-6R) is approved by the Food and Drug Administration for treatment of cytokine storm associated with chimeric antigen receptor T-cell therapy. Here we examined compassionate use of tocilizumab in patients with SARS-CoV-2 pneumonia.
Methods: We report on a single-center study of tocilizumab in hospitalized patients with SARS-CoV-2 pneumonia. All patients had confirmed SARS-CoV-2 pneumonia and oxygen saturations <90% on oxygen support with most intubated. We examined clinical and laboratory parameters including oxygen and vasopressor requirements, cytokine profiles, and C-reactive protein (CRP) levels pre- and post-tocilizumab treatment.
Results: Twenty-seven SARS-CoV-2 pneumonia patients received one 400 mg dose of tocilizumab. Interleukin (IL)-6 was the predominant cytokine detected at tocilizumab treatment. Significant reductions in temperature and CRP were seen post-tocilizumab. However, 4 patients did not show rapid CRP declines, of whom 3 had poorer outcomes. Oxygen and vasopressor requirements diminished over the first week post-tocilizumab. Twenty-two patients required mechanical ventilation; at last follow-up, 16 were extubated. Adverse events and serious adverse events were minimal, but 2 deaths (7.4%) occurred that were felt unrelated to tocilizumab.
Conclusions: Compared to published reports on the morbidity and mortality associated with SARS-CoV-2, tocilizumab appears to offer benefits in reducing inflammation, oxygen requirements, vasopressor support, and mortality. The rationale for tocilizumab treatment is supported by detection of IL-6 in pathogenic levels in all patients. Additional doses of tocilizumab may be needed for those showing slow declines in CRP. Proof of efficacy awaits randomized, placebo-controlled clinical trials.
Keywords: COVID-19; SARS-CoV2; acute respiratory distress syndrome; interleukin 6.
【저자키워드】 COVID-19, SARS-CoV2, acute respiratory distress syndrome, interleukin 6, 【초록키워드】 Treatment, SARS-CoV-2, Inflammation, Respiratory distress syndrome, Efficacy, Cytokine storm, coronavirus, therapy, Mortality, acute respiratory distress syndrome, mechanical ventilation, Tocilizumab, Pneumonia, IL-6, clinical trials, C-reactive protein, CRP, oxygen, cytokine, drug, hospitalized patients, severe acute respiratory syndrome Coronavirus, interleukin 6, Food and Drug Administration, adverse events, outcomes, Randomized, oxygen saturation, interleukin, morbidity, Patient, death, Laboratory parameters, Placebo, temperature, morbidity and mortality, Follow-up, T-cell, SARS-CoV-2 pneumonia, respiratory, patients, placebo-controlled, chimeric antigen receptor, compassionate use, acute respiratory distress, food, dose, Decline, respiratory distress, antigen receptor, C-reactive protein (CRP, Oxygen requirements, Serious Adverse Events, Serious Adverse Event, acute respiratory syndrome, Intubated, Adverse, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, significant reductions, rationale, profiles, oxygen saturations, Drug administration, IL-6R, Preliminary data, pathogenic, clinical and laboratory parameters, single-center study, proof, declines, oxygen support, offer, vasopressor support, benefit, laboratory parameter, event, anti-IL-6R, vasopressor requirements, occurred, examined, required, approved, supported, appear, hospitalized patient, reducing, predominant, Significant reduction, patients with SARS-CoV-2, vasopressor requirement, 【제목키워드】 SARS-CoV-2, Tocilizumab, Pneumonia,